This study was designed to determine whether the levels of renin-angiotensin system (RAS) components are associated with Alzheimer’s disease (AD) pathology. Cerebrospinal fluid levels of Angiotensin (Ang) II, Ang-(1-7), angiotensin-converting enzyme (ACE), ACE2, Amyloid-β (Aβ)40, Aβ42, total tau (hTau), and phospho-tau (pTau) were measured in 18 patients with AD and 10 controls. Patients with AD presented decreased levels of ACE when compared with controls. We found a significant positive correlation between ACE and Aβ42 levels among patients. Our results strengthen the hypothesis that ACE is associated with Aβ pathology in AD.
PolancoJC, LiC, BodeaLG, Martinez-MarmolR, MeunierFA, GotzJ (2018) Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies. Nat Rev Neurol14, 22–39.
5.
LiNC, LeeA, WhitmerRA, KivipeltoM, LawlerE, KazisLE, WolozinB (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ340, b5465.
6.
KumeK, HanyuH, SakuraiH, TakadaY, OnumaT, IwamotoT (2012) Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int12, 207–214.
7.
ZhuangS, WangHF, WangX, LiJ, XingCM (2016) The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer’s disease: A meta-analysis. J Clin Neurosci33, 32–38.
8.
BraszkoJJ, WincewiczD, JakubowP (2013) Candesartan prevents impairment of recall caused by repeated stress in rats. Psychopharmacology (Berl)225, 421–428.
9.
WincewiczD, BraszkoJJ (2014) Telmisartan attenuates cognitive impairment caused by chronic stress in rats. Pharmacol Rep66, 436–441.
10.
WincewiczD, BraszkoJJ (2015) Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress. J Renin Angiotensin Aldosterone Syst16, 495–505.
11.
WincewiczD, JuchniewiczA, WaszkiewiczN, BraszkoJJ (2016) Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression. Pharmacol Biochem Behav148, 108–118.
12.
KurataT, LukicV, KozukiM, WadaD, MiyazakiK, MorimotoN, OhtaY, DeguchiK, YamashitaT, HishikawaN, MatsuzonoK, IkedaY, KamiyaT, AbeK (2015) Long-term effect of telmisartan on Alzheimer’s amyloid genesis in SHR-SR after tMCAO. Transl Stroke Res6, 107–115.
13.
OngaliB, NicolakakisN, TongXK, AboulkassimT, PapadopoulosP, Rosa-NetoP, LecruxC, ImbodenH, HamelE (2014) Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol Dis68, 126–136.
14.
KehoePG, BlairPS, HowdenB, ThomasDL, MaloneIB, HorwoodJ, ClementC, SelmanL, BaberH, LaneA, CoulthardE, PassmoreAP, FoxNC, WilkinsonIB, Ben-ShlomoY (2017) The rationale and design of the reducing pathology in Alzheimer’s disease through Angiotensin TaRgeting (RADAR) Trial. J Alzheimers Dis61, 803–814.
15.
WhartonW, GoldsteinFC, TanseyMG, BrownAL, TharwaniSD, VerbleDD, CintronA, KehoePG (2018) Rationale and design of the mechanistic potential of antihypertensives in preclinical Alzheimer’s (HEART) trial. J Alzheimers Dis61, 815–824.
16.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr CR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
17.
RochaNP, ScalzoPL, BarbosaIG, de Campos-CarliSM, TavaresLD, de SouzaMS, ChristoPP, ReisHJ, SimoesESAC, TeixeiraAL (2016) Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson’s disease. J Neurol Sci368, 235–239.
18.
DuitsFH, TeunissenCE, BouwmanFH, VisserPJ, MattssonN, ZetterbergH, BlennowK, HanssonO, MinthonL, AndreasenN, MarcussonJ, WallinA, RikkertMO, TsolakiM, ParnettiL, HerukkaSK, HampelH, De LeonMJ, SchroderJ, AarslandD, BlankensteinMA, ScheltensP, van derFlier WM (2014) The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?Alzheimers Dement10, 713–723e712.
MinersS, AshbyE, BaigS, HarrisonR, TaylerH, SpeedyE, PrinceJA, LoveS, KehoePG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: Differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res1, 163–177.
21.
ZubenkoGS, VolicerL, DirenfeldLK, FreemanM, LanglaisPJ, NixonRA (1985) Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer’s disease, Parkinson’s disease and progressive supranuclear palsy. Brain Res328, 215–221.
22.
JochemsenHM, TeunissenCE, AshbyEL, van der FlierWM, JonesRE, GeerlingsMI, ScheltensP, KehoePG, MullerM (2014) The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease. Alzheimers Res Ther6, 27.
23.
HuJ, IgarashiA, KamataM, NakagawaH (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem276, 47863–47868.
24.
KoningsCH, KuiperMA, ScheltensP, GrijpmaAM, van PeltW, WoltersEC (1993) Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with ‘probable’ Alzheimer’s disease. Eur J Clin Chem Clin Biochem31, 495–497.
25.
NielsenHM, LondosE, MinthonL, JanciauskieneSM (2007) Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis26, 27–35.
26.
MateosL, IsmailMA, Gil-BeaFJ, LeoniV, WinbladB, BjorkhemI, Cedazo-MinguezA (2011) Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer’s disease. J Alzheimers Dis24, 669–679.
27.
HeM, OhruiT, MaruyamaM, TomitaN, NakayamaK, HiguchiM, FurukawaK, AraiH (2006) ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease. Neurology67, 1309–1310.
28.
JochemsenHM, van der FlierWM, AshbyEL, TeunissenCE, JonesRE, WattjesMP, ScheltensP, GeerlingsMI, KehoePG, MullerM (2015) Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. J Alzheimers Dis44, 153–162.
29.
KehoePG, KatzovH, FeukL, BennetAM, JohanssonB, WimanB, de FaireU, CairnsNJ, WilcockGK, BrookesAJ, BlennowK, PrinceJA (2003) Haplotypes extending across ACE are associated with Alzheimer’s disease. Hum Mol Genet12, 859–867.
